Company profile
Ticker
IBO
Exchange
CEO
Mr. Todd D. Macko
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Meat-Tech 3D Ltd., MeaTech 3D Ltd.
SEC CIK
Corporate docs
IRS number
853926944
IBO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
8 Oct 24
8-K
Impact BioMedical Inc. Announces Pricing of Initial Public Offering
17 Sep 24
424B4
Prospectus supplement with pricing info
17 Sep 24
EFFECT
Notice of effectiveness
16 Sep 24
S-1/A
IPO registration (amended)
27 Aug 24
8-A12B/A
Registration of securities on exchange (amended)
23 Aug 24
S-1/A
IPO registration (amended)
20 Aug 24
10-Q
2024 Q2
Quarterly report
13 Aug 24
S-1/A
IPO registration (amended)
9 Aug 24
CERT
Certification of approval for exchange listing
9 Aug 24
Latest ownership filings
4
Change in insider ownership
19 Sep 24
4
Change in insider ownership
18 Sep 24
3/A
Initial statement of insider ownership (amended)
18 Sep 24
3
Initial statement of insider ownership
17 Sep 24
3
Frank D Heuszel
16 Sep 24
3
David K Keene
16 Sep 24
3
Jason Grady
16 Sep 24
3
Elise Brownell
16 Sep 24
3
Castel Berisford Hibbert
16 Sep 24
3
Todd D Macko
16 Sep 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.00 k | 2.00 k | 2.00 k | 2.00 k | 2.00 k | 2.00 k |
Cash burn (monthly) | (no burn) | 83.33 | 294.67 k | 360.00 k | 222.00 k | 206.83 k |
Cash used (since last report) | n/a | 306.58 | 1.08 mm | 1.32 mm | 816.72 k | 760.92 k |
Cash remaining | n/a | 1.69 k | -1.08 mm | -1.32 mm | -814.72 k | -758.92 k |
Runway (months of cash) | n/a | 20.3 | -3.7 | -3.7 | -3.7 | -3.7 |
Press releases
Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
15 Oct 24
Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates
7 Oct 24
Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue
26 Sep 24
Impact BioMedical Inc. Announces the Closing of its Initial Public Offering
17 Sep 24
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value
16 Sep 24